The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions.

Autor:	Iyer SG; Department of Medicine, Division of Hematology, University of Miami Miller School of Medicine, Miami, FL, United States.; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, United States., Elias L; University of Miami Miller School of Medicine, Miami, FL, United States., Stanchina M; Department of Medicine, Division of Hematology, University of Miami Miller School of Medicine, Miami, FL, United States.; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, United States., Watts J; Department of Medicine, Division of Hematology, University of Miami Miller School of Medicine, Miami, FL, United States.; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2023 Jan 18; Vol. 12, pp. 1062524. Date of Electronic Publication: 2023 Jan 18 (Print Publication: 2022).
DOI:	10.3389/fonc.2022.1062524
Abstrakt:	The transformation of acute promyelocytic leukemia (APL) from an often fatal to highly curable cancer with long-term survival exceeding 90% is one of the greatest and most inspiring successes in oncology. A deeper understanding of the pathogenesis of APL heralded the introduction of highly effective therapies targeting the mutant protein that drives the disease, leading to the chemotherapy-free approach to cure almost all patients. In this review, we discuss the paradigm of treatment of APL in 2023, reinforce the high risk of early death without prompt initiation of treatment at first clinical suspicion, and dedicate a special focus to novel agents and future directions to improve cure rates and quality of life in patients affected by APL. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Iyer, Elias, Stanchina and Watts.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu